[AI] Fw: <ayurvedaonline> Re:Stem Cells Theraphy.

P. Subramani subramani6912 at gmail.com
Wed Jul 18 13:10:21 EDT 2007

Dear listers, I am forwarding this message from a very distinguished Dr. His reply is to my question about the pros and cons of Stem Cells Theraphy. Hope this will be useful to all. Please read fully. The message is self-explanatory.
----- Original Message ----- 
From: dr.aashish phadke 
To: P. Subramani 
Sent: Tuesday, July 17, 2007 1:59 AM
Subject: Re: <ayurvedaonline> Re:Stem Cells Theraphy.

Dear Mr.P.Subramani, 
No problems ! I am sending herewith the modern informations connected to Stem Cell Therapy & RP & other related topics !Please go thro' the same ! 

Please find one more news to STAY AWAY from the Dr.Sapse's Stem Cell Pharma Inc.  The advice is very simple-DONT TAKE ANY ACTION IN DESPERATION!

Reliable sources strongly believe that a proper strategies for treating genetic disorders like RP should arrive in a span of 2-4 years.

 We will be also including some recommendations on antioxidants therapy by Retina South Africa, which you can give a try safely.

I am sending you a forward note of Mr. Gislin, associate professor, department of ophthalmology, John Hopkins University, USA about Dr. Alfred T Sapse, Owmer of Stem Cell Pharma Inc. in the following attachment. This note is self explainatory. Please send the copy of this forward note to other members.
Kind regard
             --------Forward note----------
Dear xxxx,   The company
 obtains stemcells from umbilical cord blood and injects these cells into patients withvarious diseases including RP. There is absolutely no evidence, scientific or otherwise, that this provides anybenefit to these patients.  But they are desperate, and willing to pay. Dr. Sapse has been given an ultimatum in the US that he has to stop treatingpeople, but apparently he still takes patients to mexico where he treats themin a clinic just across the
 border. If you want my opinion, I think you should stay as far away from Stem CellPharma as you can, and you should warn other patients not to fall into thistrap.  And you should challenge the company to submit evidence in supportof their "beneficial" treatment. Gislin  On 2 Jun 2007 at 11:21, md musfic wrote:>>  Dear Mr. Gislin,> I have received a news that stem cell pharma inc, a US based company
 bas formed a joint> venture with an Indian company to start a new RP center in India to treat RP patients by using> stem cell implant on October, 2007 which has been published in the company's> website(www.stemcellpharmainc.com). The company also bas claimed that they are successfully> treating RP patients by using FDA approved clinical procedure and will hire the doctors who are> M.D. from US to conduct clinical trial in India. Please make comment on this issue.> Kind
 regard> XXX--Gislin Dagnelie, Ph.D.Associate Professor of Ophthalmology<!--[if !supportEmptyParas]--> <!--[endif]-->
This section brings out the latest research information related to Retinal Degeneration.
  a.. Potential Cure for Visually Challenged Children Moves into a Human Study
Children born visually challenged, from a devastating retinal condition called Leber congenital amaurosis (LCA) may soon be able to see thanks to an innovative gene replacement therapy that has just moved into a clinical trial. 
The study, funded in part by the Foundation Fighting Blindness, is being conducted by University College of London and Moorfields Eye Hospital in London. Two additional Foundation-funded clinical trials are scheduled to begin soon at the University of Pennsylvania and the Children's Hospital of Philadelphia.
"This is one of the most important milestones ever reached in retinal research, because it offers the promise of giving vision to children who otherwise would never see," says Bill Schmidt, Chief Executive Officer, Foundation Fighting Blindness. "We are thrilled to be at this hopeful juncture."
"Not only does gene replacement hold promise for LCA, the same approach may be used to treat a variety of other retinal diseases including retinitis pigmentosa, Stargardt disease, Usher syndrome, and age-related macular degeneration," says Stephen Rose, Ph.D., Chief Research Officer, Foundation Fighting Blindness. "The success of these studies in the U.S. and the U.K. can pave the way for many more treatments to save and restore vision in millions of people around the world."
(Source:- Adapted from Article of Ben Shaberman from FFB Webstite) 
  a.. Human Neural Stem Cells Show Potential for Vision Rescue
An FFB-funded research team from the University of Wisconsin and the University of Utah used human neural stem cells - cells derived from the brain - to rescue vision in a rodent model of retinal degenerative disease. 
A team of investigators including David Gamm, M.D., Ph.D., Ray Lund, Ph.D., Clive Svendsen, Ph.D., and Shaomei Wang, Ph.D., says that human neural stem cells offer promise for slowing vision loss in humans affected by a variety of retinal degenerative diseases including retinitis pigmentosa and age-related macular degeneration.
Plans are underway to study human neural stem cells for treating retinal diseases in more rodent models and a larger animal model - important steps before the treatment approach can be evaluated in a human trial
(Source:- Adapted from Article of Ben Shaberman from FFB Webstite) 
  a.. Neurotech begins Phase II/III human studies of treatment for retinitis pigmentosa
Neurotech Pharmaceuticals, Inc. has begun enrollment of participants in two multicenter Phase II/III human clinical trials for an innovative treatment to slow the progression of a group of blinding diseases known as retinitis pigmentosa. Both studies are partially funded by the Foundation Fighting Blindness. 
Neurotech's treatment involves implantation of a tiny device known as Encapsulated Cell Technology (ECT) into the eye. Less than a quarter-of-an-inch long, the ECT implant contains retinal cells which provide long-term, sustained delivery of a vision-saving protein known as ciliary neurotrophic factor (CNTF).
In preclinical studies supported by the Foundation Fighting Blindness, the treatment exhibited a safe and effective profile. The therapy also performed well in a Phase I human study conducted at the National Eye Institute.
(Source:- Adapted from Article of Ben Shaberman from FFB Webstite) 
  a.. Eye Drop Attacks AMD on Three Fronts
An eye drop developed by Othera Pharmaceuticals holds potential for being a uniquely effective treatment for age-related macular degeneration (AMD), because it is believed to address three factors that can cause the vision-robbing condition - inflammation, oxidative stress, and unhealthy blood vessel growth (angiogenesis). 
Al Reaves, Ph.D., Senior Vice President, Clinical Development at Othera, says that the studies show that OT-551 treatment may be effective for treating both the dry and wet forms of AMD. He notes that for dry AMD, it is providing a treatment option where few others currently exist. For wet AMD, the eye drops may enhance the effectiveness of other wet AMD therapies.
(Source:- Adapted from Article of Ben Shaberman from FFB Website)
  a.. Umbilical Cord Tissue Shows Promise as Retinal Disease Treatment
The umbilical cord is not only the lifeline for a developing baby, but it might also save sight for people affected by a variety of retinal degenerative diseases. 
Because the umbilical cord is normally discarded after birth, use of the tissue derived from it doesn't raise ethical concerns.
FFB-funded investigator Ray Lund, Ph.D., Oregon Health and Science University, in collaboration with Centocor, a biomedicine company, used human umbilical cord tissue (hUTC) to rescue vision in a rodent model of retinal degenerative disease. 
In a paper published in the March 1, 2007 issue of Stem Cells, the investigative team reported that "hUTC may provide utility in treating patients with retinal degenerations such as retinitis pigmentosa."
The research team also evaluated mesenchymal (bone marrow) and placental cells for retinal rescue. Mesenchymal cells were somewhat effective, but Lund says they are more difficult to expand and produce than hUTC. Placental cells had little effect.
(Source:- Adapted from Article of Ben Shaberman from FFB Website) 
  a.. Tests Begin On Next Generation Of Retinal Implant
(Ivanhoe Newswire) -- The FDA has approved the next step of a study that will help people who have lost vision from macular degeneration or retinitis pigmentosa regain some of their sight.
Researchers from the University of Southern California in Los Angeles are investigating an implanted artificial retina, called the Argus II Retinal Prosthesis System. It's the second generation of an electronic retinal implant to treat blindness by replacing photoreceptors. Photoreceptor cells in the retina process light and are required for sight. In conditions like retinitis pigmentosa, those photoreceptors deteriorate.
The updated version of the implant contains 60 electrodes, which Dr. Humayun reports he believes will result in higher resolution images for the patients. The new implant is also smaller than the original, which will reduce surgery and recovery time.
Dr. Humayun reports the implant will ultimately be used for people with age-related macular degeneration (AMD). He reports: "Perhaps what we're most excited about in this next study is, similar to the first generation ... device, we will be able to test the new device with patients at their homes, churches, schools and similar locations. The importance of this work is going to be reflected in how well this helps them regain some of their lost vision."
(Source: Presented at the American Association for the Advancement of Science annual meeting in San Francisco, Feb. 15-19, 2007)
  a.. Emerging Therapy Knocks Out Disease-Causing Gene in Dominant RP
Foundation-funded researchers from the University of Florida have made an important advancement in the development of gene therapy to treat people with autosomal dominant retinitis pigmentosa (ADRP). The emerging treatment involves shutting down the disease-causing gene so it no longer leads to the production of a toxic protein in the retina that causes photoreceptor death and vision loss. The treatment, known as ribozyme therapy, was shown to be effective in mice, and specifically targets ADRP caused by variations in the rhodopsin (RHO) gene.
One of the benefits of this ribozyme therapy is that it could be used to treat most people with ADRP caused by variations (mutations) in RHO. Scientists estimate that there are more than 100 different mutations in RHO that can cause ADRP, so it is a big plus to have a therapy that can potentially treat them all. Though this emerging ribozyme treatment is targeted for RHO, the therapy can also be adapted to treat people whose ADRP is caused by variations in other genes
(Source:- Adapted from Article of Ben Shaberman from FFB Website)
  a.. DHA to be Studied as Treatment for X-Linked RP
An FFB-funded investigative team from the Retina Foundation of the Southwest is conducting a Phase II clinical trial of docosahexaenoic acid (DHA) for the treatment of X-linked retinitis pigmentosa (XLRP).  
Some retinal experts believe that DHA supplementation may slow the progress of XLRP and other forms of retinal degenerative disease including age-related macular degeneration and the dominant form of Stargardt disease.  
DHA is an omega-3 fatty acid that is abundant in the retinas of humans and other mammals, and is important for optimal retinal health. People can obtain DHA through dietary supplements or the consumption of coldwater fish such as salmon, tuna, or mackerel.  
(Source:- Adapted from Article of Ben Shaberman from FFB Website)
  a.. Emerging AMD Treatments Bring Promise of Saving and Restoring Sight 
Years of laboratory research and clinical studies are now resulting in new drugs that are helping patients with wet age-related macular degeneration (AMD) save, and in some cases, improve their vision. 
The FDA's recent approval of LucentisT brings another new drug treatment to millions of people at risk of losing their sight to wet AMD. Results from a large, two-year study showed that Lucentis halted vision loss in more than 90 percent of individuals with the wet form of age-related macular degeneration (AMD). The treatment actually restored vision in 33 percent of those study participants.
Lucentis becomes the second alternative in a group of emerging treatments that slow the growth of vision-robbing blood vessels under the retina, which is the tragic hallmark of wet AMD. Approved by the FDA in late 2004, Macugen was the first of these drugs, and studies have shown that it halts vision loss in about 70 percent of wet AMD cases.  
(Source:- Adapted from Article of Ben Shaberman from FFB Website)
  a.. British Scientist plan strategy with Stem Cells 
British scientists plan to use stem cells to cure a common form of blindness, with the first patients receiving test treatment in five years. The pioneering project, aims to repair damaged retinas with cells derived from human embryonic stem cells. Its backers say it involves simple surgery that could one day become as routine as cataract 
(Source:- LONDON (Reuters)
  a.. Research in Germany related to Retinal Chip brings hope 
Tübingen Blind people can perceive initial impressions of vision again with a
retinal chip. This is the result of a development by Retina Implant GmbH, the
University Eye Hospital in Tübingen and further project partners. A tiny microelectronic
chip, which has been implanted directly under the retina of initially
seven blind patients since autumn 2005, replaces the photoreceptor cells which
have perished and is intended to return part of the patients' vision. The study results
from the patients are now providing statements of the function of active microelectronic implants in the human eye.
(Source:- Retina International)

With Warm Regards,
Dr.Aashish Phadke,Mumbai,India

<!--[if !supportEmptyParas]--> <!--[endif]-->

"P. Subramani" <subramani6912 at gmail.com> wrote:
  Thank you Dr. Ashish for your great knowledge. Actually I had learnt about your treatment as far back as in 1993/4. But unfortunately, I lost your contact details and couldn't get further. I specifically wish to know the pros and cons of Stem Cells Theraphy as it is quite a recent phenomenon as I am thinking to go for this system of treatment for my RP. 
    ----- Original Message ----- 
    From: dr.aashish phadke 
    To: ayurvedaonline at yahoogroups.com 
    Sent: Sunday, July 15, 2007 6:05 PM
    Subject: <ayurvedaonline> Re:Stem Cells Theraphy.

    Dear Mr.Subramani,
    I am working on this problem for last 12 yrs. I had prsented my research paper in the Ayurveda World Congress 06 at Pune as well. I can say that if you are keen in knowing more about the contribution of Ayurveda in RP , please visit the following links & if possible become a member of that group - 
    To read little more on this you may visit these links for my articles related to this topic - 

    Thanking you,
    With warm regards,
    Prof.Dr.Aashish Phadke,Mumbai,India
    Ayurveda - Yoga _ Eye Consultant

    Messages in this topic (0) Reply (via web post) | Start a new topic 
    Messages | Links | Polls | Members 
    Wishing you the best of Health.

    Change settings via the Web (Yahoo! ID required) 
    Change settings via email: Switch delivery to Daily Digest | Switch format to Traditional 
    Visit Your Group | Yahoo! Groups Terms of Use | Unsubscribe Recent Activity
      a..  11New Members
    Visit Your Group 
      a.. Health problem 
      b.. Health problem in cat 
      c.. Health problem in dog 
      d.. Ayurveda 
      e.. Wellness 
    FruitaBü Parents
    on Yahoo! Groups
    teaching families
    how to eat healthy.
    Yahoo! 360°
    Get Started
    Create your page
    Share your life
    Yahoo! Groups
    Moderator Central
    Connecting a world
    of moderators. 

Get the free Yahoo! toolbar and rest assured with the added security of spyware protection. 

More information about the AccessIndia mailing list